ASCO GU 2024

BRCAAway - practice changing or hypothesis generating data?

Combination vs. monotherapy - a great new option for high-risk patients

Cabo + IO: Interesting but not practice changing?!

Is "more" always better?

Evaluating the recombination-repair mutations in patients with mCRPC

What about the clinical benefit?

Olaparib + Arbiraterone better compared to either alone

Stockholm3 validated in multiethnic cohort

Insights and news for mCRPC

BRCAaway - PARP combination study

Higher radiation is effective in high-risk PCA

Therapy Intensification Still Neglected in mHSPC

First positive study of IO therapy in mCRPC

Gleason 3+3 - cancer or not?

Relugolix combined with androgen signaling in real word experience

Enzalutamide therapy as option for biochemical recurrence

Long-term dose escalation - Therapy in high-risk prostate cancers

Salvage radiation with anti-androgen superior to radiation alone

Combination of cabozantinib & checkpoint inhibitor

Localized PCa - news for radiotherapy and biochemical recurrence

Combination NHT + PARP makes sense

Still a difficult time for androgenic inhibitors in mCRPC

Further testing before olaparib combination

Dose de-escalation in different ways

Quality of life under intensive therapy

Cognitive function in ART treatment

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

Kombination av cabozantinib och immunterapi

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

Gleason 3+3 ska vi kalla de cancer eller inte?

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Kognitiv påverkan av abirateron och enzalutamid?

BRCAAway - PARP hämmare, abiraterone eller i kombination

ADC + ICI: new data for platinum-refractory bladder cancaer patients

New standard of care, but still open questions!

Advances in (neo)-adjuvant treatment in urothelial cancer

The emerging field of biomarkers in bladder cancer

ASCO GU24 - Highlights in Bladder cancer

MIBC: adjuvant PD1 - all set?!

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

Biomarker update

Update on EV-302

Another success for an ICI?

Perioperative adjuvant therapy in urothelial cancer

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Update M1 urothelial cancer

Highlights in bladder cancer at ASCO GU24

Pembrolizumab adjuvant in bladder cancer

EV + Pembro new first-line standard in localized metastatic bladder cancer

HER2 and bladder cancer

EV as standard in 3rd line mUC

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Novedades sobre EV-302

Terapia adyuvante perioperatoria en el cáncer de vejiga

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

Subcutaneous vs. intravenous application: ready for everyday clinics?

No surprise with the QoL data

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Highlights in kidney cancer at ASCO GU24

Perioperative treatment in renal cell carcinoma - did we close the circle?

Practice changing adjuvant therapy?!

ASCO GU24 - Highlights in renal cell carcinoma

Long-term follow-up of first-line trials

Long-Term Data on NIVO+IPI in aRCC

Tumorburden and outcome

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Better QoL with Belzutifan

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Long-term outcome

Durable effects of Ipi-Nivo

Overall survival benefit - Pembro after surgery

Belzutifan: Updates on QoL

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?